Guggenheim Capital’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-25,224
| Closed | -$653K | – | 1747 |
|
|
2025
Q4 | $653K | Buy |
+25,224
| New | +$600K | ﹤0.01% | 1148 |
|
|
2024
Q3 | – | Sell |
-16,855
| Closed | -$482K | – | 1923 |
|
|
2024
Q2 | $482K | Buy |
+16,855
| New | +$480K | ﹤0.01% | 1449 |
|
|
2023
Q3 | – | Sell |
-47,229
| Closed | -$1.89M | – | 1898 |
|
|
2023
Q2 | $1.89M | Buy |
47,229
+4
| +0% | +$165 | 0.01% | 880 |
|
|
2023
Q1 | $1.93M | Sell |
47,225
-1,744
| -4% | -$69.4K | 0.02% | 859 |
|
|
2022
Q4 | $1.89M | Buy |
+48,969
| New | +$2.38M | 0.02% | 878 |
|
|
2022
Q2 | – | Sell |
-65,765
| Closed | -$5.02M | – | 2114 |
|
|
2022
Q1 | $5.02M | Buy |
65,765
+1,305
| +2% | +$87K | 0.03% | 653 |
|
|
2021
Q4 | $3.88M | Sell |
64,460
-27,408
| -30% | -$1.51M | 0.02% | 786 |
|
|
2021
Q3 | $5.14M | Sell |
91,868
-2,482
| -3% | -$143K | 0.03% | 648 |
|
|
2021
Q2 | $5.72M | Buy |
94,350
+64,284
| +214% | +$4.07M | 0.03% | 628 |
|
|
2021
Q1 | $2.11M | Sell |
30,066
-9,243
| -24% | -$660K | 0.01% | 1003 |
|
|
2020
Q4 | $2.35M | Buy |
+39,309
| New | +$2.3M | 0.01% | 899 |
|
|
2018
Q4 | – | Sell |
-52,296
| Closed | -$2.57M | – | 2323 |
|
|
2018
Q3 | $2.57M | Sell |
52,296
-8,949
| -15% | -$387K | 0.02% | 1102 |
|
|
2018
Q2 | $1.96M | Sell |
61,245
-7,461
| -11% | -$258K | 0.01% | 1269 |
|
|
2018
Q1 | $2.14M | Buy |
68,706
+12,112
| +21% | +$431K | 0.01% | 1584 |
|
|
2017
Q4 | $2.58M | Sell |
56,594
-22,528
| -28% | -$893K | 0.01% | 1475 |
|
|
2017
Q3 | $2.97M | Buy |
79,122
+13,255
| +20% | +$533K | 0.01% | 1390 |
|
|
2017
Q2 | $3.14M | Buy |
65,867
+10,557
| +19% | +$490K | 0.01% | 1292 |
|
|
2017
Q1 | $2.52M | Sell |
55,310
-13,278
| -19% | -$574K | 0.01% | 1483 |
|
|
2016
Q4 | $2.21M | Sell |
68,588
-239
| -0.3% | -$7.97K | 0.01% | 1595 |
|
|
2016
Q3 | $2.35M | Sell |
68,827
-2,141
| -3% | -$83.9K | 0.01% | 1515 |
|
|
2016
Q2 | $2.39M | Buy |
70,968
+5,790
| +9% | +$285K | 0.01% | 1452 |
|
|
2016
Q1 | $3.45M | Buy |
65,178
+22,368
| +52% | +$1.31M | 0.01% | 1205 |
|
|
2015
Q4 | $3.29M | Buy |
42,810
+33,606
| +365% | +$1.9M | 0.01% | 1265 |
|
|
2015
Q3 | $378K | Sell |
9,204
-40,747
| -82% | -$2.5M | ﹤0.01% | 2510 |
|
|
2015
Q2 | $3.53M | Buy |
49,951
+7,819
| +19% | +$616K | 0.01% | 1350 |
|
|
2015
Q1 | $3.74M | Buy |
42,132
+8,642
| +26% | +$877K | 0.01% | 1326 |
|
|
2014
Q4 | $2.97M | Buy |
33,490
+20,339
| +155% | +$1.92M | 0.01% | 1442 |
|
|
2014
Q3 | $1.27M | Buy |
13,151
+2,046
| +18% | +$199K | ﹤0.01% | 2074 |
|
|
2014
Q2 | $1.02M | Buy |
+11,105
| New | +$846K | ﹤0.01% | 2251 |
|
|
2013
Q3 | – | Sell |
-21,406
| Closed | -$621K | – | 3156 |
|
|
2013
Q2 | $621K | Buy |
+21,406
| New | +$619K | ﹤0.01% | 2319 |
|
Other funds holding PCRX
DPCM
VPM
VCM
